提醒成功
微信/QQ登錄
搜索
首頁
| 產品規范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00002 |
| Application | Flow cytometry, animal model study |
| Aliases | Anti-EGFR Chimeric Monoclonal Antibody |
| Size/Concentration | 1mg/5mg/20mg |
| clone | C225 |
| Isotype | Human IgG1 |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human EGFR / ErbB-1 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations. Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked. |
Cetuximab Biosimilar, Human EGFR Monoclonal Antibody B00002
聯系方式
CONTACT-
聯系電話:
0731-88388785 -
公司郵箱:
sales@promab.cn -
公司地址:
湖南省長沙市高新開發區林語路239號順暢產業園5樓
官方微信
產品中心
Product技術服務
service客戶留言
message